Abstract
Background: Despite recent advances in improved glycemic control, the magnitude of lifetime risk from premature cardiovascular disease in individuals with type 1 diabetes remains at least 10 fold higher than in the general population. The availability of lipoprotein fractionation has allowed the spotlight for this increased risk to shift from dysglycemia to diabetes-induced dyslipidemia associated with insulin resistance. Interventions designed to simultaneously improve both factors can have distinct and additive effects on slowing the initiation and progression of atherosclerotic lesions. As fullblown cardiovascular disease is not evident during childhood, there is a critical need to identify the most predictable surrogate markers that could assign elevated risk, as well as the design of safe and targeted interventions that could improve outcomes in this population.
Conclusion: This review will examine the evidence supporting the notion that cardiovascular disease in type 1 diabetes is associated with significant insulin resistance and it begins in childhood, making it necessary to design rational clinical trials that will significantly reduce risk in this population.
Keywords: Cardiovascular disease, dyslipidemia, HbA1c, insulin resistance, lipoproteins, statins, systematic review, type 1 diabetes.
Current Diabetes Reviews
Title:Interventions to Reduce Cardiovascular Risk in Children with Type 1 Diabetes
Volume: 13 Issue: 6
Author(s): Jose A. Canas, Samuel S. Gidding and Nelly Mauras*
Affiliation:
- Pediatric Endocrinology, Diabetes & Metabolism, Nemours Children's Health System, 807 Children's Way, Jacksonville, FL 32207,United States
Keywords: Cardiovascular disease, dyslipidemia, HbA1c, insulin resistance, lipoproteins, statins, systematic review, type 1 diabetes.
Abstract: Background: Despite recent advances in improved glycemic control, the magnitude of lifetime risk from premature cardiovascular disease in individuals with type 1 diabetes remains at least 10 fold higher than in the general population. The availability of lipoprotein fractionation has allowed the spotlight for this increased risk to shift from dysglycemia to diabetes-induced dyslipidemia associated with insulin resistance. Interventions designed to simultaneously improve both factors can have distinct and additive effects on slowing the initiation and progression of atherosclerotic lesions. As fullblown cardiovascular disease is not evident during childhood, there is a critical need to identify the most predictable surrogate markers that could assign elevated risk, as well as the design of safe and targeted interventions that could improve outcomes in this population.
Conclusion: This review will examine the evidence supporting the notion that cardiovascular disease in type 1 diabetes is associated with significant insulin resistance and it begins in childhood, making it necessary to design rational clinical trials that will significantly reduce risk in this population.
Export Options
About this article
Cite this article as:
Canas A. Jose, Gidding S. Samuel and Mauras Nelly*, Interventions to Reduce Cardiovascular Risk in Children with Type 1 Diabetes, Current Diabetes Reviews 2017; 13 (6) . https://dx.doi.org/10.2174/1573399813666170113142621
DOI https://dx.doi.org/10.2174/1573399813666170113142621 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vitamin D and Vitamin D Receptor Activators in Treatment of Hypertension and Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Editorial: [Hot Topic: Establishment of the Australian Infectious Diseases Research Centre]
Current Drug Targets Bioprocess and Bioreactor: Next Generation Technology for Production of Potential Plant-based Antidiabetic and Antioxidant Molecules
Current Medicinal Chemistry Clinical Science of Calcium Channel Blocker to Inhibit Hypertensive Vascular Injury
Current Hypertension Reviews “Cardiovascular” Drugs in Rheumatoid Arthritis: Killing Two Birds with One Stone?
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Benefits of SGLT2 Inhibitors Beyond Glycemic Control – A Focus on Metabolic, Cardiovascular and Renal Outcomes
Current Diabetes Reviews Cellular Cardiomyoplasty and Cardiac Regeneration
Current Cardiology Reviews Editorial (A New Era for Medicinal Chemistry)
Mini-Reviews in Medicinal Chemistry Mechanisms for Progenitor Cell-Mediated Repair for Ischemic Heart Injury
Current Stem Cell Research & Therapy Recent Patents on Hypocholesterolemic Therapeutic Strategies: An Update
Recent Advances in DNA & Gene Sequences (Discontinued) Therapeutic Potential of Modulating MicroRNA in Peripheral Artery Disease
Current Vascular Pharmacology Macrophage Differentiation to Foam Cells
Current Pharmaceutical Design A Review on Post Pregnancy Healer Herbs
Current Women`s Health Reviews Epigenetics in Medullary Thyroid Cancer: From Pathogenesis to Targeted Therapy
Recent Patents on Anti-Cancer Drug Discovery Subject Index To Volume 3
Vascular Disease Prevention (Discontinued) Mevalonate Cascade and Neurodevelopmental and Neurodegenerative Diseases: Future Targets for Therapeutic Application
Current Molecular Pharmacology Use of Bipolar Radiofrequency Catheter Ablation in the Treatment of Cardiac Arrhythmias
Current Cardiology Reviews Oxidative and Nitrosative Stress and Immune-inflammatory Pathways in Patients with Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS)
Current Neuropharmacology The Metabolic Treatment of Patients with Coronary Artery Disease: Effects on Quality of Life and Effort Angina
Current Pharmaceutical Design Balancing Antioxidant, Hypolipidemic and Anti-inflammatory Activity in a Single Agent: The Example of 2-Hydroxy-2-Substituted Morpholine, 1,4-Benzoxazine and 1,4-Benzothiazine Derivatives as a Rational Therapeutic Approach against Atherosclerosis
Current Medicinal Chemistry